Design of the Redefining Therapy in Early COPD Study

Area of Science:

• Pulmonology
• Respiratory Medicine
• Clinical Trials

Background:

• Chronic Obstructive Pulmonary Disease (COPD) significantly impacts quality of life, even in early stages with preserved spirometry.
• Symptomatic patients with COPD Assessment Test (CAT) scores ≥ 10 despite normal spirometry represent an under-treated population.
• Current therapeutic strategies may not adequately address the needs of these specific COPD patients.

Purpose of the Study:

• To assess the efficacy and safety of indacaterol/glycopyrrolate in symptomatic current and former smokers with early COPD.
• To evaluate the impact of the study drug on respiratory symptoms, quality of life, and lung function.
• To determine the proportion of patients achieving a significant improvement in St George's Respiratory Questionnaire (SGRQ) score without treatment failure.

Main Methods:

• A 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study (RETHINC).
• Inclusion criteria: symptomatic COPD (CAT score ≥ 10), current/former smokers, preserved spirometry (FEV1/FVC ratio ≥ 0.70).
• Primary endpoint: proportion of individuals with a 4-unit SGRQ improvement at 12 weeks without treatment failure. Secondary endpoints included CAT, BDI, TDI scores, and spirometry measures.

Main Results:

• The study enrolled 580 participants to evaluate indacaterol/glycopyrrolate efficacy and safety.
• Primary endpoint analysis focused on SGRQ score improvement and treatment failure rates.
• Secondary endpoints assessed changes in CAT, BDI, TDI scores, and lung function parameters like FEV1 and inspiratory capacity.

Conclusions:

• Indacaterol/glycopyrrolate offers a potential new therapeutic avenue for managing symptomatic early COPD patients with preserved spirometry.
• The RETHINC study provides critical data on the efficacy and safety profile of this combination therapy in a distinct COPD subpopulation.
• Results are anticipated to redefine therapeutic approaches for patients experiencing respiratory symptoms despite seemingly normal lung function tests.